Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 1

Changing Landscape of Endometrial Cancer: Incidence and Classification

,

Dive into the evolving landscape of endometrial cancer, including rising incidence, classification, racial disparities, and emerging modalities, as discussed by experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD.

Now Viewing
EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer

Related Content:

Optimizing Therapy for Endometrial Cancer: Recent Data HighlightsNYU Langone's Perlmutter Cancer CenterGynecologic OncologyInsights
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer
Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors